The most frequently used approach to produce scFv and Fab in E. coli is to express them in the periplasm of the bacteria. We present here an alternative procedure that uses cytoplasmic expression of soluble active scFv. This can be accomplished either by using a specially engineered E. coli strains or hyperstable scFvs.
Introduction
Escherichia coli is the host of choice for laboratory production of antibody fragments.
Despite recent advances in the production of whole antibody molecules in E. coli (1), the most frequently used format is the scFv or the Fab. These fragments retain the whole antibody binding site and usually bind to the antigen with an affinity comparable to that of the parental antibody molecule.
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When expressed in B cells, antibodies are secreted molecules containing glycosylations and disulfide bonds. Glycosylations are required for the effector functions and are mainly located in the Fc fragment. Since this part of the antibody is not present in both scFv and Fab molecules, the absence of glycosylation modifications in E. coli is not an obstacle to their production in this host. There are two kinds of disulfide bonds in antibody molecules, interand intra-domain. Inter-domain disulfide bonds link together the heavy and light chains and are present in Fab but not in scFv, and intra-domain disulfide bonds are a hallmark of the so called "immunoglobulin fold" and are present in two copies in scFv and four copies in Fab.
The intra-domain disulfide bond is crucial for the stability of the antibody molecule. Indeed, reduction of the two disulfide bonds of a scFv results in a decrease of about 5 kcal/mol which is close to the intrinsic stability of many antibody domains (2). This explains why the first successful expression of active antibody fragments in E. coli has been obtained in the periplasm of the bacteria where disulfide formation is promoted by the dsb machinery (3). This is still the most frequently used approach to produce scFv and Fab in E. coli (4).
An alternative approach to produce antibody fragments in E. coli is to express them in the cytoplasm. It has been known for years that much higher expression levels can be obtained in this compartment, albeit usually as aggregated and/or inactive molecules. The main explanation is presumably the absence of disulfide bond formation in the reducing environment of the cytoplasm, resulting in unstable antibody fragments, either aggregated or quickly degraded by the cell. There are however other factors that may influence the production of antibody fragments in the cytoplasm like the kinetic competition between folding, aggregation and degradation (5,6).
In the recent years, two approaches have been developed to improve the production of active antibody fragments in E. coli cytoplasm: the use of E. coli mutant strains that promote disulfide bond formation in the cytoplasm, and the selection and engineering of hyperstable inserm-00418812, version 1 -21 Sep 2009 3 antibody fragments. Of course both approaches can be combined by expressing hyperstable antibody fragments in such mutant E. coli strains.
In E. coli, the reducing environment of the cytoplasmic compartment is maintained by the thioredoxin and the glutathione pathways. Using elegant genetic selections, Jon Beckwith and collaborators (3) selected a triple mutant strain containing knockouts in the two pathways (trxB and gor) but with a compensatory point mutation in the ahpC gene that allowed an almost normal growth of the bacteria. This E. coli strain allows the expression of scFv and Fab fragments at levels comparable to that obtained in the periplasm.
We will describe a step-by-step procedure to test the expression of your antibody fragment in E. coli cytoplasm, then to purify it. We usually use scFv but the approach could also be used for Fab fragments. It is worth noting that this approach will be particularly successful if the intrinsic stability of your scFv is in the upper range of the values obtained for scFv molecules. This should be the case if your scFv has been selected from optimized libraries (7-10) or if the VH is from human families 1,3 or 5 (11).
Materials
1. scFv cloned in a pET derived vector (see Note 1).
2. BL21(DE3), BL21(DE3)pLys, Origami (DE3), Origami (DE3)pLysS (see Note 2).
3. LBG plates: 10 g tryptone (peptone), 5 g yeast extract, 10 g NaCl, make up to 1 liter with water, adjust pH to 7.0 with 5 N NaOH, add 15 g of agar and autoclave. Allow the solution to cool to 60 °C or less, add 50 ml of 40% glucose solution (autoclaved), suitable antibiotics (100 μg/ml ampicillin and eventually 25 μg/ml of chloramphenicol), then pour the plates.
4. Ampicillin: Dissolve 1 g of ampicillin (sodium salt) in 10 ml of ultrapure water.
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Filter-sterilize (0.22 μm) and store in 1 ml aliquots at -20 °C (see Note 3).
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. Chloramphenicol: 25 mg/ml in 95% ethanol. Store at -20 °C.
6. 17 mm x 100 mm 14 ml sterile culture tubes (e.g. VWR #211-0085).
7. ZY: 10 g N-Z-amine AS (or any tryptic digest of casein, e.g. tryptone/peptone), 5 g yeast extract, 925 ml water. Autoclave. 12. TE: Tris 50 mM, EDTA 1 mM pH 8. Store at 4 °C.
13. 10 mg/ml Lysozyme solution in TE (see Note 6).
Benzonase (see Note 7).
15. 5 M NaCl.
16. 10% Nonidet P-40 (w/v). Store at RT.
1 M Imidazol in water (see Note 8).
18. Nickel Affinity Gel (see Note 9). 3. Grow with vigorous agitation at 37 °C until the OD 600nm reaches .4 (see Note 13).
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4. Grow overnight at 24 °C with vigorous agitation (see Note 14).
5. Transfer in 1.5 ml microtubes and centrifuge for 5 min at 5,000 g at 4 °C. Remove the supernatant by aspiration and proceed with "Small scale cell lysis" (see Note 15).
Small scale cell lysis
All the steps must be done at 4 °C, either on ice or in a cold-room.
1. Freeze/Thaw the pellet twice in a dry ice/ethanol bath (see Note 16).
2. Resuspend carefully the pellet in 100 μl of cold TE by pipetting up and down or/and by vortexing.
3. Add 10 μl of a 3 mg/ml solution of Lysozyme (see Note 6 & 17).
4. Incubate for 1 h on ice.
5. Add 7 μl of 5 M NaCl. Mix gently.
6. Add 7.5 μl of 10% Nonidet P-40. Mix gently.
7. Add 10U/ml Benzonase (i.e., 1 U) and incubate 10-15 min RT (see Note 7 & 18).
8. Centrifuge for 15 min at 13,000 g at 4 °C.
Transfer the supernatant in a clean tube (see Note 19).
10. Analyze the soluble fractions to determine the best expression system (see Note 20).
Large-scale purification
All the steps must be done at 4 °C, either on ice or in a cold-room. 11. Centrifuge for 30 min at 16,000 g at 4 °C.
12. Filter using a 0.45 μm filter mounted on a 20 ml syringe (see Note 23).
13. Add 460 μl of a 1 M imidazol solution.
14. Apply on a 2 ml equilibrated "Metal Chelate Affinity" column (see Note 9).
15. Wash with 10 ml of WB.
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vector pET23d(+) from Novagen. The resulting scFv will be tagged at its C-terminal extremity with a 6 Histidine tag that will be used for the purification in protocol 3.3.
A modified vector that adds an extra c-myc tag for easy detection using the 9E10
antibody is available on request (pET23NN: (6)). 14. To maintain the temperature at 24 °C a refrigerated shaker is required. If it is not available, you can shake your flask at RT or at the lowest possible temperature that you can maintain in your shaker (usually about 27 °C).
The four
15. You can stop at this step and freeze the pellets at -20 °C for later processing.
16. If dry ice is not available, you can freeze the pellet once at -20 °C. Thaw the pellet in a RT water bath for 5 min.
17. You can omit this step if your strain contains the pLys plasmid since the T7 lysozyme expressed from this plasmid will be sufficient for an efficient lysis.
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18. It is also possible to keep the tube on ice but longer incubation time will be necessary.
Alternatively, for large scale purifications, draw the lysate through a narrow-gauge syringe needle several times to reduce viscosity. 
